Monoclonal gammopathy of ocular significance (MGOS) – a short survey of corneal manifestations and treatment outcomes

References

• Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362–1369.
   PubMed Web of Science ®Google Scholar
• Landgren O, Graubard BI, Katzmann JA, et al. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia. 2014;28(7):1537–1542.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249.
   PubMed Web of Science ®Google Scholar
• Robert AK, Shaji K. The significance of monoclonal gammopathy of undetermined significance. Haematologica. 2009;94:1641–1644.
   PubMed Web of Science ®Google Scholar
• Leung N, Bridoux F, Batuman V, et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol. 2019;15(1):45–59.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Callander NS, Baljevic M, et al. The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance. Am J Hematol. 2021;96(7):846–853.
   PubMed Web of Science ®Google Scholar
• Lipsker D. Monoclonal gammopathy of cutaneous significance: review of a relevant concept. J Eur Acad Dermatol Venereol. 2017;31(1):45–52.
   PubMed Web of Science ®Google Scholar
• Karakus S, Gottsch JD, Caturegli P, et al. Monoclonal gammopathy of “ocular” significance. Am J Ophthalmol Case Rep. 2019;15:100471.
   PubMedGoogle Scholar
• Wang TP, Safran SG, Richter JR, et al. Subepithelial corneal immunoglobulin deposition as a manifestation of multiple myeloma: a case report and literature review. Clin Lymphoma Myeloma Leuk. 2014;14(1):e39–e42.
   PubMedGoogle Scholar
• Balderman SR, Lichtman MA. Unusual manifestations of monoclonal gammopathy: I. Ocular disease. Rambam Maimonides Med J. 2015;6(3):e0026.
   PubMed Web of Science ®Google Scholar
• Thuro BA, Sagiv O, Shinder R, et al. Clinical presentation and anatomical location of orbital plasmacytomas. Ophthal Plast Reconstr Surg. 2018;34(3):258–261.
   PubMed Web of Science ®Google Scholar
• Lisch W, Wasielica-Poslednik J, Kivelä T, et al. The hematologic definition of monoclonal gammopathy of undetermined significance in relation to paraproteinemic keratopathy (an American Ophthalmological Society Thesis). Trans Am Ophthalmol Soc. 2016;114:T7.
   PubMedGoogle Scholar
• Mansour AM, Arevalo JF, Badal J, et al. Paraproteinemic maculopathy. Ophthalmology. 2014;121(10):1925–1932.
   PubMed Web of Science ®Google Scholar
• Regulation on the protection of natural persons with regard to the processing of personal data and on the free movement of such data (general data protection regulation). In: 2016/679. Edited by parliment TE. Official Journal of the European Union. 2016; p. 1–88.
   Google Scholar
• Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467–1473.
   PubMed Web of Science ®Google Scholar
• Lewis RA, Hultquist DE, Baker BL, et al. Hypercupremia associated with a monoclonal immunoglobulin. J Lab Clin Med. 1976;88(3):375–388.
   PubMed Web of Science ®Google Scholar
• Kavoussi SC, Kovacs KD, Alasil T, et al. Delayed bilateral fibrinous anterior chamber reaction following autologous bone marrow transplant and cataract surgery. Am J Ophthalmol Case Rep. 2016;2:8–10.
   PubMedGoogle Scholar
• Hemminki K, Försti A, Tuuminen R, et al. The incidence of senile cataract and glaucoma is increased in patients with plasma cell dyscrasias: etiologic implications. Sci Rep. 2016;6:28500.
   PubMed Web of Science ®Google Scholar
• Ho AC, Benson WE, Wong J. Unusual immunogammopathy maculopathy. Ophthalmology. 2000;107(6):1099–1103.
   PubMed Web of Science ®Google Scholar
• Shakin EP, Augsburger JJ, Eagle RC Jr, et al. Multiple myeloma involving the iris. Arch Ophthalmol. 1988;106(4):524–526.
   PubMedGoogle Scholar
• Tranos PG, Andreou PS, Wickremasinghe SS, et al. Pseudohypopyon as a feature of multiple myeloma. Arch Ophthalmol. 2002;120(1):87–88.
   PubMedGoogle Scholar
• Chan JH, Dua HS, Tranos PG, et al. Pseudohypopyon due to malignant infiltration of the anterior chamber in multiple myeloma. Eye (Lond). 2005;19(1):112–113.
   PubMed Web of Science ®Google Scholar
• Munteanu G. [Doyne’s macular heredodystrophy and benign monoclonal gammopathy. Genetic and pathogenetic correlations (author’s transl)]. J Fr Ophtalmol. 1980;3(12):753–758.
   PubMed Web of Science ®Google Scholar
• Ogata N, Ida H, Takahashi K, et al. Occult retinal pigment epithelial detachment in hyperviscosity syndrome. Ophthalmic Surg Lasers. 2000;31(3):248–252.
   PubMedGoogle Scholar
• Agorogiannis EI, Kotamarthi V. Paraproteinemia and central retinal vein occlusion. Hippokratia. 2015;19:92.
   PubMed Web of Science ®Google Scholar
• Khaouly S, Vilaplana D. Uveal effusion associated with an IgM lambda subtype monoclonal gammopathy. Arch Soc Esp Oftalmol. 2014;89(9):382–386.
   PubMedGoogle Scholar
• Maatouk I, He S, Hummel M, et al. Patients with precursor disease exhibit similar psychological distress and mental HRQOL as patients with active myeloma. Blood Cancer J. 2019;9(2):9.
   PubMedGoogle Scholar
• Larsen RF, Jarden M, Minet LR, et al. Physical function in patients newly diagnosed with multiple myeloma; a Danish cohort study. BMC Cancer. 2020;20(1):169–169.
   PubMed Web of Science ®Google Scholar
• Popat R, Kazantzi A, Farooq A, et al. Ocular health of patients with Relapsed/Refractory Multiple Myeloma (RRMM): baseline data from the DREAMM-2 trial of belantamab mafodotin (belamaf). Blood. 2020;136(Supplement 1):43–44.
   Google Scholar
• Pennisi M, Berchicci L, Miserocchi E, et al. Ocular disorders in multiple myeloma patients: cross-sectional study of prevalence and association with treatment. Leuk Lymphoma. 2019;60(2):477–482.
   PubMed Web of Science ®Google Scholar
• Milman T, Kao AA, Chu D, et al. Paraproteinemic keratopathy: the expanding diversity of clinical and pathologic manifestations. Ophthalmology. 2015;122(9):1748–1756.
   PubMed Web of Science ®Google Scholar
• Skalicka P, Dudakova L, Palos M, et al. Paraproteinemic keratopathy associated with monoclonal gammopathy of undetermined significance (MGUS): clinical findings in twelve patients including recurrence after keratoplasty. Acta Ophthalmol. 2019;97(7):e987–e992.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood. 2015;125(20):3069–3075.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Durie BG, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24(6):1121–1127.
   PubMed Web of Science ®Google Scholar
• Wasielica-Poslednik J, Gericke A, Desuki A, et al. Recurrence of paraproteinemic keratopathy after penetrating keratoplasty and its assessment with confocal microscopy. Am J Ophthalmol Case Rep. 2018;11:87–91.
   PubMedGoogle Scholar
• Chiang HH, Wieland RS, Rogers TS, et al. Paraproteinemic keratopathy in monoclonal gammopathy of undetermined significance treated with primary keratoprosthesis: case report, histopathologic findings, and world literature review. Medicine (Baltimore). 2017;96(50):e8649.
   PubMed Web of Science ®Google Scholar
• Beebe WE, Webster RG Jr, Spencer WB. Atypical corneal manifestations of multiple myeloma. A clinical, histopathologic, and immunohistochemical report. Cornea. 1989;8(4):274–280.
   PubMed Web of Science ®Google Scholar